Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a protein that forms toxic aggregates and spreads between cells, damaging them. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), held from March 17 to 21, 2026, in Copenhagen, several strategies were presented that aim to modify the course of the disease and offer real alternatives to purely symptomatic treatments.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Belief Biomed, Fluoguide, GSK, Livanova, Nia, Remix, Sarepta.
Clinical updates for biopharma and med tech, including data readouts and publications: AC Immune, AL-S Pharma, C2N, Causeway, Clearmind, Kelun-Biotech, Pfizer, Totus, Vaxcyte.
RSS
